259 results about "Defensin" patented technology

Methods and compositions for modulating development and defense responses are provided. Nucleotide sequences encoding defensin proteins are provided. The sequences can be used in expression cassettes for modulating development, developmental pathways, and defense responses. Transformed plants, plant cells, tissues, and seed are also provided.

The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.

The invention mainly relates to an application of defensins to an aspect of preparation of a medicine for treating metabolic syndrome. Inventiveness and exploitativeness of the invention are reflected in that human derived alpha defensins 5 and 6 is supplemented via oral administration to balance intestinal flora ecology, so that system inflammation is reduced; insulin resistance is relieved; the fatty liver is ablated; and blood fat and blood sugar are reduced. The invention further provides a method for preparing the alpha defensins 5 and 6, and the application of the alpha defensins 5 and 6 to the medicine for treating related diseases.

The present invention relates to recombinant expression of defensin antimicrobial peptides in fermentation of filamentous fungi.

No antiviral regimen has been consistently successful in treating H5N1 virus infection. We demonstrate that a group of highly effective siRNAs targeting different H5N1 viral genes shares a unique motif, GGAGU/ACUCC. We further demonstrate that the effectiveness of siRNAs containing this motif is not sequence specific. The results suggested that the structure of the unique motif is critical in determining the potency of siRNA-mediated protective effects against viral infection and this potent in vivo protection is associated with early productions of β-defensin and IL-6 induced by the motif. Provided are methods and prophylactic and therapeutic agents useful against other viral infections in addition to the H5N1 influenza virus.

Drug compositions for treatment of one or more inflammatory conditions can includes at least one of a θ-defensin, analog or derivative thereof. Inventive methods include researching θ-defensins, analogs or derivatives thereof for their efficacy with respect to anti-inflammatory effects, and providing such compositions to the marketplace for the purpose of treating inflammatory conditions. Of particular interest are drug compositions effective to produce clinically relevant inhibition of tumor necrosis factor alpha (TNF-α)-converting enzyme (TACE) or other proinflammatory proteases, and/or sheddases. it is contemplated that preferred compositions can be used to treat rheumatoid arthritis, inflammatory bowel disease, and other chronic inflammatory diseases, autoimmune diseases, cancer, and Alzheimer's, osteoarthritis, inflammation-related neurodegenerative and other inflammation-related diseases.

The invention provides lipopeptid which comprises a peptide chain and an aliphatic chain which are connected through peptide bonds, wherein the molecular weight of the lipopeptid is 2848Da, and the lipopeptid is linear, and can obviously introduce the expression of phylaxin, and effectively inhibit staphylococcus aureus infection so as to prevent or reduce skin infection. The invention also discloses a derivative of the lipopeptid and preparation methods and application of the lipopeptid and the derivative of the lipopeptid.

The invention discloses a reagent kit and a method for detecting human alpha defensin 1/3 gene copy number. The reagent kit comprises a first group of primers, i.e. target gene real-time fluorescence quantitative PCR (Polymerase Chain Reaction) amplification primers, a first fluorescent probe, i.e. a target gene real-time fluorescence quantitative PCR amplification fluorescent probe, a second group of primers, i.e. a reference gene real-time fluorescence quantitative PCR amplification primers, a second fluorescent probe, i.e. a target gene real-time fluorescence quantitative PCR amplification fluorescent probe, a calibration sample DNA (Deoxyribose Nucleic Acid), and real-time fluorescence quantitative PCR reaction liquid, wherein base sequences of the first group of primers is shown by SEQ (Sequence) ID (Identity) No. 1 and 2; a middle probe base sequence is shown by SEQ ID No. 3; base sequences of the second group of primers are shown by SEQ ID No. 4 and 5; a middle probe base sequence is shown by SEQ ID No. 6. The reagent kit for detecting the human alpha defensin 1/3 gene copy number has the advantages of simplicity, convenience and quickness in use, no standard curve required, high sensitivity and specificity, good repeatability and high detection efficiency and can be used for indicating the risk prediction of clinical infection immune diseases.

The invention relates to defensin cathelicidin-PP of polypedates puerensis as well as a gene and application thereof, and belongs to the field of biomedicine. The defensin cathelicidin-PP is a cyclic polypeptide encoded by a gene of defensin of Chinese amphibian polypedates puerensis, and has a molecular weight of 3,366.08 daltons and an isoelectric point of 10.05; the amino acid sequence of the defensin cathelicidin-PP is as shown by SEQ ID NO: 1. A gene GenBank Accession KY610282 for encoding a precursor of the defensin cathelicidin-PP of the polypedates puerensis consists of 615 nucleotide sequences; the nucleotide sequence of the gene GenBank Accession KY610282 is as shown by SEQ ID NO: 2, wherein nucleotides at No. 346 to No. 441 sites are encoding genes of defensin cathelicidin-PP of mature polypedates puerensis. The invention relates to the application of the defensin cathelicidin-PP of the polypedates puerensis to the preparation of a therapeutic medicine for infectious diseases caused by escherichia coli, salmonella paratyphi A, pseudomonas aeruginosa and candida glabrata. The defensin cathelicidin-PP has the obvious effects of inhibiting the growth of a bacterium and a fungus for the escherichia coli, the salmonella paratyphi A, the pseudomonas aeruginosa and the candida glabrata.

A cationic antimicrobial peptide (CAMP) conjugate is disclosed. The CAMP conjugate may be made by identifying a suitable carrier peptide; identifying a suitable antimicrobial agent; creating a conjugate by conjugating the peptide with the antimicrobial agent; and evaluating and refining the conjugate. The peptide may be short peptide based on the sequence of a CAMP, such as human β-defensin-3. The peptide can be directly connected to the antimicrobial agent or through a linker segment. The antimicrobial agent may be connected to the peptide or the linker segment through stable or cleavable bonding. The peptide may carry and facilitate the delivery of the conjugated antimicrobial agent to a microbe.

The invention expresses a refitted rabbit defensin NP-1 (mNP-1) by using chlorella. The defensin expressed in chlorella has a very strong inhibiting or killing effect on Gram-negative bacteria, Gram-positive bacteria and the like, and can be used for killing medicament-resistant bacteria. A result of the invention can be applied to preparation of a medicament which is resistant to the Gram-negative bacteria and the Gram-positive bacteria, and can be applied to preparation of medicament which is resistant to super bacteria.

Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.